Literature DB >> 10467380

The Guy's Neurological Disability Scale (GNDS): a new disability measure for multiple sclerosis.

B Sharrack1, R A Hughes.   

Abstract

A postal survey showed that the majority of 49 leading international neurologists involved with multiple sclerosis research felt that currently existing outcome measures for this illness were inadequate, and that there was a need for a new measure which should be patient orientated, multidimensional, and not biased towards any particular disability. The Guy's Neurological Disability Scale (GNDS) was subsequently devised as a simple and user-friendly clinical disability scale capable of embracing the whole range of disabilities which could be encountered in the course of multiple sclerosis. It has 12 separate categories which include cognition, mood, vision, speech, swallowing, upper limb function, lower limb function, bladder function, bowel function, sexual function, fatigue, and 'others'. The GNDS was found to be acceptable to neurologists and patients, reliable, responsive, and valid as a measure of disability. The scale was also found to be valid when applied by non-neurologists, over the phone, or via a postal questionnaire.

Entities:  

Mesh:

Year:  1999        PMID: 10467380     DOI: 10.1177/135245859900500406

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  59 in total

1.  Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational, international, multi-centre study.

Authors:  Peter J Jongen; Dirk Lehnick; Evert Sanders; Pierette Seeldrayers; Sten Fredrikson; Magnus Andersson; Joachim Speck
Journal:  Health Qual Life Outcomes       Date:  2010-11-15       Impact factor: 3.186

2.  A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale.

Authors:  R C Graham; R A C Hughes
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-03-30       Impact factor: 10.154

3.  Multiple sclerosis in the UK: service use, costs, quality of life and disability.

Authors:  Paul McCrone; Margaret Heslin; Martin Knapp; Paul Bull; Alan Thompson
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

4.  Validation of mood measures for people with multiple sclerosis.

Authors:  Tessa M Watson; Emma Ford; Esme Worthington; Nadina B Lincoln
Journal:  Int J MS Care       Date:  2014

5.  The INTERMED: a screening instrument to identify multiple sclerosis patients in need of multidisciplinary treatment.

Authors:  E L J Hoogervorst; P de Jonge; B Jelles; F J Huyse; I Heeres; H M van der Ploeg; B M J Uitdehaag; C H Polman
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-01       Impact factor: 10.154

6.  One year changes in disability in multiple sclerosis: neurological examination compared with patient self report.

Authors:  E L J Hoogervorst; M J Eikelenboom; B M J Uitdehaag; C H Polman
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-04       Impact factor: 10.154

7.  Case studies in cardiac dysfunction after acute aneurysmal subarachnoid hemorrhage.

Authors:  Jason C Hamilton; Lauren Korn-Naveh; Elizabeth A Crago
Journal:  J Neurosci Nurs       Date:  2008-10       Impact factor: 1.230

8.  A randomised controlled trial comparing rehabilitation against standard therapy in multiple sclerosis patients receiving intravenous steroid treatment.

Authors:  J Craig; C A Young; M Ennis; G Baker; M Boggild
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-09       Impact factor: 10.154

9.  Omega-3 fatty acids and multiple sclerosis: relationship to depression.

Authors:  Robin L Aupperle; Douglas R Denney; Sharon G Lynch; Susan E Carlson; Debra K Sullivan
Journal:  J Behav Med       Date:  2008-04

10.  Rasch analysis of the Multiple Sclerosis Impact Scale MSIS-29.

Authors:  Melina Ramp; Fary Khan; Rose Anne Misajon; Julie F Pallant
Journal:  Health Qual Life Outcomes       Date:  2009-06-22       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.